Teva Pharmaceutical Industries Limited
Financials
Valuation Metrics
Teva Pharmaceutical Industries Limited's Market Cap is $49.00B. At end of 2025 it was $35.86B. Ranked #327 of 3,116 in US market (top 10%), #235 of 1,644 on NYSE (top 14%), #19 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 7%) by Market Cap.
Investment Metrics(as of 2026-10-30)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $49.00B | US#327/3,116 Sec#19/265 |
| Revenue | $17.31B | US#367/3,116 Sec#15/265 |
| Net Income | $706M | US#681/3,116 Sec#25/265 |
| Total Assets | $39.86B | US#379/3,116 Sec#17/265 |
| Net Assets | $7.76B | US#510/3,116 Sec#20/265 |
| Employees | 32,008 | US#373/3,116 Sec#13/265 |
| Value | ||
| P/E | 69.40x | US#1,995/3,116 Sec#58/265 |
| P/B | 6.32x | US#2,360/3,116 Sec#160/265 |
| P/S | 2.83x | US#1,605/3,116 Sec#45/265 |
| EV/EBITDA | 23.99x | US#2,045/3,116 Sec#55/265 |
| FCF Yield | 2.75% | US#1,857/3,116 Sec#59/265 |
| Profitability | ||
| ROE | 9.10% | US#1,462/3,116 Sec#49/265 |
| ROA | 1.77% | US#1,703/3,116 Sec#66/265 |
| Op. Margin | 11.45% | US#1,460/3,116 Sec#59/265 |
| Revenue Growth | 4.13% | US#1,845/3,116 Sec#117/265 |
| Financial Health | ||
| Debt Ratio | 413.77% | US#2,276/3,116 Sec#219/265 |
| Total Debt | $16.87B | US#263/3,116 Sec#16/265 |
| FCF | $1.35B | US#479/3,116 Sec#24/265 |
| Cash | $3.65B | US#264/3,116 Sec#15/265 |
| Current Ratio | 0.88x | US#2,404/3,116 Sec#258/265 |
| Net Debt/EBITDA | 5.10x | US#2,023/3,116 Sec#76/265 |
| Performance | ||
| 1Y Return | 110.08% | US#138/3,116 Sec#32/265 |
| 1M Return | 6.26% | US#1,390/3,116 Sec#92/265 |
| From 52W High | -1.14% | US#150/3,116 Sec#11/265 |
| 1Y MDD | -21.79% | US#760/3,116 Sec#26/265 |
| Trading | ||
| Volume | 6,068,197 shares | US#402/3,116 Sec#33/265 |
| Trading Value | $255M | US#559/3,116 Sec#25/265 |
| Per Share | ||
| EPS | $0.61 | US#1,822/3,116 Sec#57/265 |
| BPS | $6.66 | US#2,122/3,116 Sec#104/265 |
Company Info
Teva Pharmaceutical Industries Limited functions as a global pharmaceutical enterprise, involved in the conception, manufacturing, marketing, and provision of a broad spectrum of generic, specialty, and biopharmaceutical products throughout North America, Europe, and various international markets. The company's diverse product range includes sterile items, hormones, potent drugs, and cytotoxic agents, available in numerous forms like tablets, capsules, injectable solutions, inhalable preparations, liquids, transdermal patches, topical ointments, and creams. Additionally, Teva develops, produces, and sells active pharmaceutical ingredients (APIs). The firm prioritizes several key therapeutic domains: central nervous system disorders, pain management, respiratory ailments, and oncology. In the central nervous system sector, prominent products include Copaxone, intended for relapsing forms of multiple sclerosis; AJOVY, prescribed for preventing migraines; and AUSTEDO, which targets tardive dyskinesia and chorea linked to Huntington's disease. For respiratory conditions, Teva offers medications such as ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick, all designed to treat asthma and chronic obstructive pulmonary disease. The oncology portfolio features therapies like Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited is also engaged in a collaboration with MedinCell to advance and commercialize multiple long-acting injectable formulations, notably a risperidone suspension for individuals affected by schizophrenia. The company was established in 1901 and its primary headquarters are located in Tel Aviv-Yafo, Israel.